Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 3:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 704 matching trials from the live ClinicalTrials.gov search.
Conditions
End-Stage Renal Disease (ESRD)
Interventions
Avacopan
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Miami Lakes, Florida • Orlando, Florida
Completed No phase listed Observational

T Wave Alternans in Hemodialysis

NCT00296543
Conditions
End Stage Renal Disease, Coronary Heart Disease, Congestive Heart Failure
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
End-stage Renal Disease
Interventions
Alpha, gamma, beta, and delta (mixed) tocopherols, Alpha lipoic acid, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Hepatitis C, Chronic
Interventions
Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
12
States / cities
Birmingham, Alabama • Kansas City, Kansas • New Orleans, Louisiana + 9 more
Conditions
Renal Dialysis
Interventions
Heparin N reduction
Drug
Lead sponsor
Randolph Quinn
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
New Haven, Connecticut • New York, New York • Houston, Texas + 1 more
Conditions
End-Stage Renal Disease, Stage 5 Chronic Kidney Disease
Interventions
Telavancin, Pharmacokinetic Blood Sampling
Drug · Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
End Stage Renal Disease
Interventions
ChoironeX GalKO Porcine Thymokidney
Biological
Lead sponsor
Xeno Holdings (US), LLC dba ChoironeX
Industry
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
New York, New York
Completed Not applicable Interventional Results available

Cook Enforcer Post-Market Study

NCT03552289
Conditions
End-Stage Renal Disease
Interventions
Cook Advance® Enforcer 35 Focal-Force Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter, Conventional angioplasty balloon catheters
Device
Lead sponsor
Cook Research Incorporated
Industry
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Phoenix, Arizona • Darien, Connecticut • Newark, Delaware + 2 more
Completed Not applicable Interventional Results available

Post-Approval Study for the FLAIR Endovascular Stent Graft

NCT00677235
Conditions
Stenosis of Vascular Prosthetic Devices, Implants and Grafts
Interventions
FLAIR Endovascular Stent Graft, PTA
Device · Procedure
Lead sponsor
C. R. Bard
Industry
Eligibility
21 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Bamberg, South Carolina
Conditions
End Stage Renal Disease
Interventions
kineret, placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Secondary Hyperparathyroidism Due to Renal Causes, Chronic Kidney Diseases, Vitamin D Deficiency, Stage 5 Chronic Kidney Disease
Interventions
Calcifediol Oral Capsule, Placebo oral capsule
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
18
States / cities
Peoria, Arizona • Phoenix, Arizona • Cypress, California + 13 more
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of N-acetylcysteine on Muscle Fatigue in Hemodialysis

NCT00440869
Conditions
End-Stage Renal Disease, Dialysis, Hemodialysis
Interventions
N-acetylcysteine, placebo
Dietary Supplement
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
San Francisco, California
Terminated Not applicable Interventional Results available

Propaten Randomized Investigation on Cost-benefit and Efficacy

NCT01601873
Conditions
End-stage Renal Disease
Interventions
PROPATEN, Standard Graft
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
5
States / cities
Little Rock, Arkansas • New Orleans, Louisiana • Cleveland, Ohio + 1 more
Conditions
Severe Life-limiting COPD, Severe Life-limiting Heart Failure, Severe Life-limiting Cirrhosis, Severe Life-limiting Malignancy, Severe Functional Impairment, End Stage Renal Disease
Interventions
Informed Assent Discussion, Usual Care with Attention Control
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
65 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
4
States / cities
Chapel Hill, North Carolina • Charleston, South Carolina • Burlington, Vermont + 1 more
Conditions
Renal Insufficiency, Kidney Diseases
Interventions
INCB054707
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 82 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Completed No phase listed Observational Accepts healthy volunteers

Testing Tissue Sodium Stores in CAPD Patients-Aims 1 & 2

NCT02212327
Conditions
End Stage Renal Disease
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Arterio-venous Fistula, Kidney Failure, Hemodialysis Access Failure
Interventions
Exercise
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
End-stage Renal Disease
Interventions
rabbit anti-thymocyte globulin - single dose, mycophenolate mofetil, rabbit anti-thymocyte globulin - 4 doses, sirolimus, tacrolimus
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Hyperphosphatemia
Interventions
Tenapanor, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 80 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
32
States / cities
Huntsville, Alabama • Riverside, California • Denver, Colorado + 28 more
Completed Not applicable Interventional Results available

The EvAluation of TaBlo In-CLinic and In-HOme

NCT02460263
Conditions
End Stage Renal Disease
Interventions
Tablo Hemodialysis System
Device
Lead sponsor
Outset Medical
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Jose, California
Conditions
Anemia of Chronic Disease
Interventions
FMX-8
Drug
Lead sponsor
FerruMax Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Arvada, Colorado • Minneapolis, Minnesota
Conditions
Antithrombotic
Interventions
Enoxaparin, unfractionated heparin (UFH), BMS-986177
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
3
States / cities
Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota
Conditions
End Stage Renal Disease
Interventions
GORE® Hybrid Vascular Graft, Non-heparin bonded synthetic graft
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Hackensack, New Jersey • Charlotte, North Carolina • Durham, North Carolina + 1 more
Conditions
End Stage Renal Disease, Chronic Kidney Disease
Interventions
Cognitive Function Testing-10 Tests, Sleep Assessment Testing, Periodic Leg Movement Syndrome Assessment
Other
Lead sponsor
Satellite Healthcare
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Mountain View, California